Novexel, AstraZeneca, Forest Laboratories deal

Under a separate deal, Forest will pay AstraZeneca $210 million to obtain rights to co-develop and commercialize CAZ-104 in North America and to eliminate milestones and royalties that would have been owed to Novexel under a prior license. Under a 2008 deal, Forest has North American rights to CEF-104, a combination of NXL104 and Forest's ceftaroline antibiotic that is in Phase I testing (see BioCentury, Jan. 28, 2008). ...